Jacob Nejtel Kaluski

Part of Takeda Pharmaceutical Co., Ltd., TKT Europe-5S AB is a Swedish company that markets, sells, and distributes pharmaceutical products. The company is based in Danderyd, Sweden. The company was founded by Jacob Nejtel Kaluski. TKT Europe-5S was acquired by Transkaryotic Therapies, Inc. on October 22, 2004 for $61 million.

Aqilion AB is a venture capital firm. The firm was founded in 2002 by Jan Ekberg and Mats G. Ringesten. It's headquartered in Helsingborg, Sweden.

Jederstrom Pharmaceuticals is a life sciences company that is developing new formulations for oral delivery of therapeutic proteins. These new formulations offer new and improved therapeutic possibilities, cost advantages and the convenience factor of oral administration. The vision of Jederstrom Pharmaceuticals is to make oral administration the method of choice for a number of key therapeutic proteins. Jederstrom Pharmaceuticals initial focus is to develop an insulin formulation for oral administration. Formulations of other well-known therapeutic proteins will then be developed. Jederstrom Pharmaceuticals' business model shall be out licensing. Jederstrom Pharmaceuticals was founded in 2001 by Gustaf Jederström, inventor of the formulation technology. Gustaf Jederström has more than 30 years experience of R&D in the pharmaceutical industry, where he has been instrumental in bringing numerous new pharmaceutical products to market.

DuoCort AB manufactures pharmaceutical products. The company is based in Helsingborg, Sweden. The Swedish company was founded by Thomas Hedner.

Centogene AG focuses on genetic and biochemical diagnostic testing services for rare hereditary disorders. The firm operates through the offices located in Freiburg, Dubai and Noida. The company was founded by Arndt Rolfs in 2006 and is headquartered in Rostock, Germany.

Glactone Pharma AB engages in the development of pipeline of novel signal transducer and activator of transcription 3 inhibitors. Its pipeline is used for immuno-oncology and for the treatment of drug resistant cancers, including castration resistant prostate cancer. The company was founded by Anders Sigvard Bjartell, Rebecka Hellsten, Martin Johansson, Eduardo Munoz, and Olov Arvid Sterner in 2012 and is headquartered in Helsingborg, Sweden.